← Back
Dianthus Therapeutics
DNTH · listed on Nasdaq · worth $5.42 billion
$79.52
+0.24% on Oct 27
No insider bought Dianthus Therapeutics stock in the last year. They sold it 33 times, $35.47 million in all.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
55.8M shares
100% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, six insiders sold Dianthus Therapeutics stock and none bought. 25 of the 33 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Marino Garcia, CEO AND PRESIDENT.
Planned sales
Form 144 notices filed for Dianthus Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Carr Edward filed to sell 20,000 shares on 17 Sep; no sale reported yet10b5-1 plan adopted 18 Jun 2026 · Notice on SEC.gov
Simrat Randhawa filed to sell 23,124 shares on 1 Sep; no sale reported yet10b5-1 plan adopted 14 Aug 2025 · Notice on SEC.gov
Director Anne McGeorge filed to sell 7,750 shares on 10 Aug; sold 7,750 by 10 Aug10b5-1 plan adopted 11 May 2026 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Dianthus Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateT. Rowe Price Investment Management12.1%Aug 7Reported stake, oldest first: 7.1% (Aug 7) → 12.1% (Aug 7)Crossed 10%
Filed by someone who owns 5% or more and does not plan to influence the company.T. Rowe Price Investment Management7.1%Aug 7
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Dianthus Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 19SoldSimon ReadAug 19 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,778 @ $117.55$326.6K
Aug 11SoldAnne McGeorgeAug 11 · Traded Aug 10 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.700 @ $111.41$78K
Aug 11SoldAnne McGeorgeAug 11 · Traded Aug 10 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.1,000 @ $110.64$110.6K
Aug 11SoldAnne McGeorgeAug 11 · Traded Aug 10 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.1,800 @ $109.30$196.7K
Aug 11SoldAnne McGeorgeAug 11 · Traded Aug 10 · Director · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,800 @ $108.38$303.5K
29 more with Pro →Analysts, earnings and news
Analysts' price target
$140.80 average
15 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$0.90 a share+$0.01
Q1 '26−$0.85 a share+$0.25
Q4 '25−$1.43 a share−$0.40
Q3 '25−$0.97 a share−$0.07